SMARCA4 and non-small cell lung carcinoma: In this study, the authors concluded that the increased sensitivity to platinum-based chemotherapy in NSCLC can be predicted through the low expression of SMARCA4/BRG1 acting as a novel biomarker and it depicts the efficacy of the drugs independent of age, stage, and histology in resectable NSCLCs; this, in turn, also encourages pathologists and oncologists on the importance of recognizing the clinicopathological features of SMARCA4-dNSCLC [30,39].